Zevra Secures MIPLYFFA Orange Book Patent Through November 2041
ZVRA•Zevra Therapeutics has listed U.S. Patent No. 11,707,456 for MIPLYFFA in the FDA’s Orange Book, securing exclusivity through November 19, 2041. The company’s pending patent extension for U.S. Patent No. 11,045,460 could further extend protection beyond 2029 if approved.
1. Orange Book Patent Listing
Zevra submitted U.S. Patent No. 11,707,456 for MIPLYFFA to the FDA’s Orange Book, granting regulatory exclusivity until November 19, 2041 and preventing generic competitors from entering the market before that date.
2. Pending Patent Term Extension
The company has applied for a patent term extension for U.S. Patent No. 11,045,460, which currently expires in 2029. The U.S. Patent and Trademark Office decision on this extension could further prolong MIPLYFFA’s market protection.
